著者

古野 孝明 半田 寛 今井 圭介

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.43, no.5, pp.260-266, 2017-05-10 (Released:2018-05-11)

参考文献数

8

被引用文献数

1 1

---

The phosphorus content of the drug was reported in the United States, and attention was paid to pharmaceutical additives. However, papers surveying the phosphorus content of drugs in Japan have not been reported. We calculated the phosphorous content in dibasic calcium phosphate hydrate (DCPH) or dibasic calcium phosphate (DCP) in amlodipine (AML) and compared the phosphorus content for each formulation. DCPH or DCP was found in all the 104 AML tablets and in 15 of the 78 AML OD tablets. On request, the pharmaceutical company revealed the amounts of DCPH or DCP in 78 of the 104 AML tablets (75.0%) and 9 of the 15 AML OD tablets (60%). The phosphorus content in AML tablets varied among the pharmaceutical companies and it tended to increase with an increase in dose. On the other hand, 63 of the 78 AML OD tablets did not contain DCPH or DCP. Furthermore, the phosphorus content in 9 of the 15 AML OD tablets containing DCPH or DCP was lower than that in AML tablets. Therefore, unnecessary phosphorus load can be avoided in dialysis patients by opting for AML OD tablets rather than AML tablets or opting for low phosphorus content AML tablets.